ARTICLE SUMMARY:
Over the past two decades, there has been a cyclicality to biotech/medtech’s inverse fortunes. When biotech returns leave investors frustrated, they turn to medical devices as a hedge, and vice versa. But these days, executives point to one reason to explain biotech’s good fortunes relative to medtech: the fact that there are so many potential acquirers of biotech firms and so few for medical device companies. Will new kinds of medtech buyers step in?
Pity Jed Cohen. The Leerink Swan investment banker had the dubious distinction of offering the medical device perspective on a financing panel at the recent IATI Biomed meeting, Israel’s leading gathering of executives from both the biopharma and medtech industries.
